Genprex

Category: Press Releases

Genprex Scheduled to Join Russell 3000® Index

Genprex is scheduled to join the U.S. broad-market Russell 3000 Index when FTSE Russell, a leading global index provider, reconstitutes its 2020 indices after the markets close on Friday, June 26.

Read More

Genprex to Present at the MoneyShow June Virtual Event

Mr. Varner will deliver an overview of the Company and provide updates on its product pipeline.

Read More

Genprex Announces Receipt of $2.5 Million in Cash from Recent Warrant Exercises

The exercised warrants include all warrants that have been issued to investors in the Company’s public financings to date and represent approximately 70% of the Company’s overall outstanding warrants.

Read More


Genprex Issues April 2020 Shareholder Letter

Company provides updates on recent regulatory, clinical, operational, and business developments

Read More

Genprex Appoints Shannon Inman as Vice President of Global Clinical Operations

Proven executive with clinical operations expertise to guide the Company’s clinical programs with gene therapies

Read More

Genprex Bolsters Board of Directors, Appoints Three Biotechnology and Healthcare Industry Leaders

These board additions will enhance the Company’s ability to execute on key corporate initiatives.

Read More

Genprex Strengthens Leadership Team with the Appointment of Two Accomplished Life Science Executives

These seasoned industry professionals combined with the company’s newly strengthened balance sheet will drive key clinical programs.

Read More

Lead Researcher Behind Genprex’s Diabetes Gene Therapy Featured in New Video Interview

Dr. George Gittes, the lead researcher and Harvard graduate that developed Genprex’s new potentially curative diabetes gene therapy, was featured in a video interview discussing the therapy.

Read More

Genprex to Present at the 2020 LD Micro Virtual Conference

Genprex will present at the third annual LD Micro Virtual Conference on Wednesday, March 4 at 1:40 p.m. EST. Genprex’s Chairman and Chief Executive Officer, Rodney Varner, will lead the company’s presentation and will be answering questions from investors.

Read More